What are the key efficacy and safety data and what do they mean for prescribers and their patients?

The ARASENS trial highlights the efficacy and safety of darolutamide in triplet therapy with ADT and docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). The trial demonstrated a significant 32.5% reduction in the risk of death and a 64% risk reduction in progression to castration-resistant prostate cancer (mCRPC). The triplet therapy delayed disease progression, pain, and the need for subsequent treatments, improving quality of life. Importantly, darolutamide showed no substantial increase in adverse events compared to doublet therapy, with excellent tolerability even in patients with poor prognostic factors. This establishes a new standard of care, offering prolonged survival with minimal toxicity.